{'fraction_non_alphanumeric': 0.01876675603217158, 'fraction_numerical': 0.0, 'mean_word_length': 6.114285714285714, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Antiprotozoal drugs in the treatment of respiratory allergy: a side that should be explored

Respiratory allergy is one of the most chronic airway diseases and a major health problem worldwide because of its prevalence, considerable impact on quality of life, disproportionate share of healthcare resources and economic burden. Besides factors such as genetic predisposition, environmental contaminants and biological aeroallergens (pollen, fungi, dust mites), the role of certain microorganisms (respiratory viruses such as respiratory syncytial virus and rhinovirus, and atypical bacteria like Mycoplasma pneumoniae and Chlamydophila pneumoniae) on both the development and the severity of respiratory allergy is a subject of continuous debate.